# EFFECT OF ANTIHYPERTENSIVE THERAPY ON COGNITIVE **DECLINE IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE**

## E. Cumbo, S. Cumbo, S.Torregrossa, D.Migliore, S.Falzone

Alzheimer and Dementia Unit - Neurodegenerative Disorders O.U., A.S.P. 2 Caltanissetta, Italy

**Objective**: The impact of antihypertensive therapy on cognitive decline in subjects with already declared Alzheimer's disease (AD) remain controversial. Although some studies have shown that use of antihypertensive drugs was associated with a reduced rate of cognitive impairment and dementia, other research found no significant difference between the active treatment and placebo groups on the incidence of dementia. The aim of the study was to evaluate prospectively the impact of antihypertensive therapy in terms of slowing down cognition decline in subjects with mild-tomoderate AD.


Baseline characteristics of the patient population (n=270)		
	AHT	No AHT
MALES (n, %) FEMALES (n, %)	50/149 (33.55) 89/149 (59.73)	52/131(39.69) 79/131 (60.30)
MEAN AGE (yr ± SD)	74.2 <u>+</u> 8.2	74.8 <u>+</u> 8.1
MEAN EDUCATION (yr ± SD)	5.2 <u>+</u> 2.9	5.3 <u>+</u> 2.7
MEAN AD DURATION (yr ± SD)	5.3 <u>+</u> 1.4	5.4 <u>+</u> 1.3
MMSE (total mean score <u>+</u> SD)	22.2 <u>+</u> 1.8	22.4 <u>+</u> 1.6

**Methods**: we conducted a prospective study including 270 outpatients suffering from AD according to the NINCDS-ARDRA criteria. Each year, cognitive functions were assessed by the MMSE during a follow-up period of 3 years. During this follow-up cognitive functioning was compared considering the use of antihypertensive therapy or not. All patients were treated with a Cholinesterase Inhibitor (ChEI), the first line therapy for AD. Patients with comorbid depression or other dementia subtypes were excluded.


**Results**: 270 (84.7%) of 297 patients completed the study. Mean age was 74 <u>+</u> 8.2 years. 62.22% of patients (168/270) were female; 102 (37.77%) were male. 52.22% (141/270) of the population used an antihypertensive therapy. At inclusion, the mean MMSE was similar in both groups (antihypertensive therapy vs no antihypertensive therapy 22.48 ± 4.54 vs 22.21 ± 4.82, p=0.56). After a 3 year followup, the cognitive decline was significantly less important among patients using antihypertensive therapy compared to those without antihypertensive therapy (MMSE scores = 22.08 <u>+</u> 5.12 vs 21.26 <u>+</u> 5.29 at 1 year; 20.92 <u>+</u> 5.64 vs 19.53 <u>+</u> 5.76 at 2 years and 18.95 <u>+</u> 6.75 vs 17.48 <u>+</u> 6.38 at 3 years, p<0.001 for all periods).

#### 3.5 <u>+</u> 1.9 HIS (total mean score <u>+</u> SD) 3.4 <u>+</u> 1.8

### Antihypertensive drugs utilized



## Variation of cognitive decline



**Discussion**: There was a significant difference in the MMSE median rate of decline for patients taking antihypertensive therapy compared to control group. ACE inhibitors and diuretics produced a slower rate of cognitive decline (p<0.001).

**Conclusions**: These results suggest a positive effect of antihypertensive therapy on cognitive function among patients suffering from AD, by slowing down cognitive decline during a long-term follow-up. Further prospective randomized studies comparing different antihypertensive to determine whether certain classes are needed antihypertensive classes provide greater benefits than others.

#### MEAN CHANGE IN MMSE SCORE FOLLOWING EXPOSURE TO DIFFERENT **ANTIHYPERTENSIVE DRUGS**

Medication	MMSE change	P value
Angiotensin- Converting Enzyme inhibit.	- 0.89	0.001
Angiotensin Receptors Blockers	- 0.42	0.014
Diuretics	- 0.52	0.016
Calcium channel blockers	- 0.38	0.083
β-blockers	- 0.21	0.018

### References

1- Shah K, Qureshi SU, Johnson M, Pankh N, Schulz PE, Kunik ME: Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacoter 2009, 7(5): 250-261.

2-Ye R, HuY, Yao A, YangY, ShiY, Jiang Y, Zhang J: Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis. Int J Clin Pract 2015, 69 (6): 674–681.

3- Gao Y, O'Caoimh R, Healy L, Kerins DM, Eustace J, Guyatt G, Sammon D, Molloy WD: Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013,3 (7):e002881. doi:10.1136/bmjopen-2013-002881.

### XLVII CONGRESSO NAZIONALE 22-25 OTTOBRE 2016 – VENEZIA



